Cholesterol-Lowering Antibody Evolocumab Cuts Heart Attack Risk in Landmark Analysis
A meta-analysis of nine randomised trials involving nearly 68,000 patients shows evolocumab dramatically lowers LDL cholesterol and reduces heart attacks ...
A meta-analysis of nine randomised trials involving nearly 68,000 patients shows evolocumab dramatically lowers LDL cholesterol and reduces heart attacks ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine